- Home
- OBIO vs MOLN Comparison
OBIO vs MOLN Comparison
Compare OBIO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBIO | MOLN |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 157.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | OBIO | MOLN |
|---|---|---|
| Price | $4.67 | $4.28 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $14.00 | $3.75 |
| AVG Volume (30 Days) | ★ 333.5K | 5.8K |
| Earning Date | 11-10-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,818,000.00 | N/A |
| Revenue This Year | $36.43 | N/A |
| Revenue Next Year | $2.56 | $1,000.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $2.20 | $3.36 |
| 52 Week High | $6.30 | $5.95 |
Technical Indicators
Market Signals| Indicator | OBIO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.93 | 53.28 |
| Support Level | $4.19 | $4.13 |
| Resistance Level | $5.42 | $4.52 |
| Average True Range (ATR) | 0.35 | 0.15 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 40.82 | 46.77 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.